Acyclovir for Cutaneous Herpes Simplex
For primary cutaneous herpes simplex in adults, use oral acyclovir 200 mg five times daily for 7-10 days; for recurrent episodes, use 200 mg five times daily for 5 days, or alternatively 400 mg three times daily or 800 mg twice daily for 5 days. 1
Primary Episode Treatment
For first clinical episodes of cutaneous herpes simplex, the evidence strongly supports systemic therapy over topical treatment. Oral acyclovir 200 mg five times daily for 7-10 days (or until clinical resolution) is the recommended regimen 1. This dosing significantly reduces duration of acute infection, lesion healing time, pain duration, and new lesion formation 2, 3.
Topical Therapy Considerations
While topical acyclovir 5% cream is available, its use is discouraged because it is substantially less effective than oral therapy 1. The evidence shows topical acyclovir cream may provide modest benefit if applied very early in first episodes (reducing pain duration from 8 to 4 days and healing time from 14 to 8 days), but oral therapy remains superior 4. The guidelines are clear: systemic acyclovir provides partial control of symptoms while topical therapy does not 1.
Recurrent Episode Treatment
For recurrent cutaneous herpes simplex, treatment benefit is limited unless initiated during prodrome or within 2 days of lesion onset. Three equivalent oral regimens are recommended 1:
- Acyclovir 200 mg orally 5 times daily for 5 days
- Acyclovir 400 mg orally 3 times daily for 5 days
- Acyclovir 800 mg orally 2 times daily for 5 days
The higher-dose, less-frequent regimens (400 mg TID or 800 mg BID) offer improved adherence without compromising efficacy, as bioavailability decreases with increasing single doses but total daily exposure remains therapeutic 2, 3.
Suppressive Therapy
For patients with frequent recurrences (≥6 episodes per year), daily suppressive therapy with acyclovir 400 mg twice daily reduces recurrence frequency by at least 75% 1. This regimen has documented safety and efficacy for up to 5 years of continuous use 2, 3. An alternative lower-dose regimen of 200 mg 3-5 times daily can be individualized to find the minimum effective dose 1.
The evidence shows that after 1 year of suppressive therapy, 45-63% of patients remained recurrence-free, with 71-87% recurrence-free in each 3-month quarter 2, 3. Research confirms that 400 mg twice daily extends median time to first recurrence from 46 days (placebo) to 118 days, representing a 53% reduction in clinical recurrences 5, 6.
After 1 year of continuous suppressive therapy, discontinue acyclovir to reassess the patient's natural recurrence rate 1.
Severe Disease
For severe cutaneous disease requiring hospitalization (extensive lesions, disseminated infection), use intravenous acyclovir 5-10 mg/kg every 8 hours for 5-7 days or until clinical resolution 1.
Special Populations
Immunocompromised Patients
HIV-infected and other immunocompromised patients may require more aggressive therapy with longer treatment courses 1. For mucocutaneous HSV in this population, moderate-to-severe disease requires IV acyclovir 5-10 mg/kg three times daily, then transition to oral therapy once lesions regress 7. Continue until complete healing.
Acyclovir-Resistant HSV
For documented acyclovir-resistant infections (primarily in immunocompromised patients), switch to foscarnet 40 mg/kg IV three times daily or 60 mg/kg IV twice daily 7.
Critical Caveats
- Timing is crucial: Treatment must begin during prodrome or within 2 days of lesion onset for recurrent episodes to provide meaningful benefit 1
- Renal function: Dose adjustment is mandatory in renal impairment, as acyclovir clearance is renal-dependent 2, 3
- Food has no effect: Acyclovir can be taken with or without food 2, 3
- Viral shedding continues: Acyclovir does not eliminate asymptomatic viral shedding or completely prevent transmission 1
- No effect on latency: Acyclovir neither eradicates latent virus nor affects subsequent recurrence risk after discontinuation 1